Targeted Recruitment and Degradation of Estrogen Receptor α by Photothermal Polydopamine Nanoparticles for Breast Tumor Ablation

Adv Healthc Mater. 2022 Oct;11(19):e2200960. doi: 10.1002/adhm.202200960. Epub 2022 Jul 19.

Abstract

The major challenges of photothermal therapy (PTT) toward clinical application are the severe skin injury and inflammation response associated with high power laser irradiation. Herein, polydopamine nanoparticles (PDA-EST and PDA-RAL) targeted to estrogen receptor α (ERα) for efficient ablation of breast tumor under a low irradiation density of 0.1 W cm-2 are reported. These nanoparticles are capable of recruiting ERα on their surface and induce a complete ERα degradation via localized heat. Owing to the ERα targetability, PDA-EST and PDA-RAL strongly suppress the proliferation of breast cancer cells without causing significant inflammation. This work provides a generalized method for enhancing PTT efficacy under low irradiation density.

Keywords: breast tumors; estrogen receptor α; photothermal therapy; polydopamine; targeted protein degradation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / therapy
  • Cell Line, Tumor
  • Estrogen Receptor alpha
  • Female
  • Humans
  • Indoles
  • Inflammation
  • Nanoparticles*
  • Phototherapy
  • Polymers

Substances

  • Estrogen Receptor alpha
  • Indoles
  • Polymers
  • polydopamine